Tango Therapeutics, Inc.

Day range

$22.28 – $23.95

Open

$23.41

Prev close

$23.34

Volume

3.1M

Market cap

$3.94B

Shares out

168.61M

P/E

—

P/S

73.13

P/B

3.84

P/FCF

—

ROE

-12.1%

ROA

-11.5%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsOct 23, 2026

  The Company observed an ORR of 82% (18 of 22 patients, with 11 of 18 confirmed partial responses ("cPRs") and 7 unconfirmed partial responses with all unconfirmed responses confirmed after the data cutoff date). Median PFS has not yet been reached. The Company also observed an 88% 9-month PFS rate and a 100% disease control rate ("DCR").

• Underwriting agreementAug 11, 2026

  On November 21, 2025, Tango Therapeutics, Inc. (the 'Company') entered into a Sales Agreement (the 'Sales Agreement') with Leerink Partners LLC (the 'Sales Agent'), with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock.

• Executive officer departureAug 6, 2026

  Dr. Barbara Weber's employment with Tango Therapeutics, Inc. (the "Company") as its Executive Chair ended on August 3, 2026 in accordance with the terms of her Amended and Restated Employment Agreement dated January 8, 2026. Consistent with the terms of the Employment Agreement, Dr. Weber is deemed to have resigned from all officer and board member positions, including as a member of Company's board of directors (the "Board") upon the termination of Dr. Weber's employment.

• Equity compensation grantJun 23, 2026

  In accordance with the Company's compensation program for non-employee directors, Mr. Azelby will receive an equity award consisting of a stock option to purchase 35,910 shares of the Company's common stock at an exercise price of $27.97 per share and a restricted stock unit ('RSU') award to acquire 5,740 shares of Common Stock. The option award will vest in thirty-six substantially equal monthly installments over three years from the date of grant, and the RSU award will vest in three equal annual installments over three years from the date of grant.

• Public offeringJun 10, 2026

  On June 9, 2026, Tango Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC and Leerink Partners LLC as representatives (the "Representatives") to the several underwriters named in the Underwriting Agreement (collectively, the "Underwriters"), relating to an underwritten offering (the "Offering") of (i) 18,166,667 shares (the "Firm Shares") of the Company's common stock, $0.001 par value per share (the "Common Stock") and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,833,395 shares of Common Stock... Each Share was offered and sold at an offering price of $30.00 before deducting underwriting discounts and commissions.

Days to cover

12.5

Short interest

44.5M

Avg volume

3.55M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Beyond Live Streaming: Tango Gives Back by Supporting Cancer Detection in Ukraine
  positiveGlobeNewswire Inc.· Oct 25, 2026
• Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
  positiveGlobeNewswire Inc.· Oct 16, 2026
• Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
  negativeZacks Investment Research· Sep 10, 2026
• Tango Releases Controlling the Sequence: The 2026 Retail Real Estate Portfolio Execution Index
  positiveGlobeNewswire Inc.· Aug 25, 2026
• Tango Therapeutics Announces Executive Chair Transition
  neutralGlobeNewswire Inc.· Aug 6, 2026